Results 71 to 80 of about 2,131 (185)

Fremanezumab for prophylaxis of migraine in adults [PDF]

Prescriber, 2020
Fremanezumab (Ajovy) is a new anti‐CGRP monoclonal antibody therapy indicated for the prophylaxis of migraine in adults. This article outlines its properties, efficacy, adverse effects and place in therapy.
openaire   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Sleep Disorders in Medication‐Overuse Headache: Prevalence and Associated Factors

European Journal of Neurology, Volume 33, Issue 7, July 2026.
Chronic insomnia and restless legs syndrome are highly prevalent in medication‐overuse headache, affecting 60% and 37% of patients respectively—significantly more than in headache controls. These sleep disorders are reversible following headache treatment with amitriptyline, candesartan, and fremanezumab, without any sleep‐specific interventions ...
Elena R. Lebedeva, Iana A. Kniazeva, Denis V. Gilev, Jes Olesen   +3 more
wiley   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1525-1536, July/August 2026.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

Efficacy and continuability of 675 mg fremanezumab administration over 2 years

The Journal of Headache and Pain
Background Real-world data on the long-term adherence to- and efficacy of fremanezumab 675 mg quarterly dosing remain scarce. Our study evaluated the efficacy of- and patient adherence to 675 mg fremanezumab for episodic migraine (EM) and chronic ...
Shohei Yoshida, Noboru Imai, Masato Keicho, Jun Kamimura, Asami Moriya, Nobuyasu Yagi, Rieko Suzuki, Takashi Konishi, Masahiro Serizawa   +8 more
doaj   +1 more source

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1628-1643, July/August 2026.
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Luigi Francesco Iannone, Marcello Silvestro, Antonio Munafò, Marina Romozzi, Pierangelo Geppetti, Antonio Russo   +5 more
wiley   +1 more source

Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis:post-hoc analysis of a prospective, real-world Greek registry

Objective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III, would differ between pre-menopausal and ...
Litsardopoulos, Pantelis, Andreou, Anna P.; id_orcid, Xiromerisiou, Georgia, Soldatos, Panagiotis, Dermitzakis, Emmanouil V., Argyriou, Andreas A., Rikos, Dimitrios, Vikelis, Michail, Rallis, Dimitrios   +8 more
core   +1 more source

Two Cases of Ischemic Complications in Abdominoplasty After Use of a New Biologic Migraine Medication

Plastic and Reconstructive Surgery, Global Open
Summary:. Abdominoplasty is a common aesthetic procedure, and ischemic complications are rare, particularly in nonsmokers. We present 2 cases of ischemic complications in nonsmoking patients treated with fremanezumab, a biologic medication for severe ...
Reetta Tuominen, MD, PhD, Virve Koljonen, MD, PhD   +1 more
doaj   +1 more source

Fremanezumab in the treatment of migraines: evidence to date.

Journal of pain research, 2019
Calcitonin gene-related peptide (CGRP) is a major player in migraine pathophysiology, and CGRP monoclonal antibodies including fremanezumab may be a safe effective preventive therapy. Phase IIb studies in episodic migraine (EM) and chronic migraine (CM) demonstrated efficacy at both the monthly 225 mg and quarterly 675 mg doses.
Robblee,Jennifer, VanderPluym,Juliana
openaire   +4 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source